

Progestogen addition during oestrogen replacement therapy--effects on vasomotor symptoms and mood.

Holst J, Bäckström T, Hammarbäck S, von Schoultz B.

Department of Obstetrics and Gynecology, University Hospital, Umeå, Sweden.

Vasomotor symptoms and mood changes were followed in 2 groups of post-menopausal women receiving cyclic replacement therapy with 3 mg/day of percutaneous oestradiol-17 beta alone or in sequential combination (days 11-21) with lynestrenol 5 mg/day. During 6 mth of therapy, daily symptom ratings were performed using a visual analogue scale technique. Serum levels of oestradiol were similar in both groups but sequential oestrogen/progestogen treatment was more efficient in suppressing vasomotor symptoms and serum gonadotropins. However, all negative mood symptoms were also more pronounced in this group. Progestogen addition may enhance the therapeutic effect on hot flushes and sweats but, at least in individual women cause unfavourable effects on mental status, mood and well-being.

Publication Types:

• Research Support, Non-U.S. Gov't

MeSH Terms:

- Affect/drug effects*
- Climacteric/blood
- Climacteric/drug effects*
- Estradiol/pharmacology*
- Female
- Humans
- Lynestrenol/pharmacology*
- Menopause/blood
- Menopause/drug effects*
- Middle Aged
- Vasomotor System/drug effects

New/Noteworthy

PubMed Services

Journals Database MeSH Database Single Citation

E-Utilities

Matcher Batch Citation

Matcher Clinical Queries

LinkOut

My NCBI

NLM Mobile

NLM Catalog

NLM Gateway TOXNET

Consumer Health Clinical Alerts

ClinicalTrials.gov

PubMed Central

Special Queries

Related Resources
Order Documents

http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=2725334&dopt=Citati... 8/12/2007

Substances:

- Estradiol
- Lynestrenol

PMID: 2725334 [PubMed - indexed for MEDLINE]

Display Citation Show 20 Sort By Send to

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer